关键词:

肾心综合征, 病情严重程度, 脑钠肽, 成纤维细胞生长因子23

Abstract:

Objective　To investigate the relationship between the severity of renocardiac syndrome and serum levels of brain natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF-23). Methods　A total of 60 patients with renocardiac syndrome admitted to Liaocheng Second People's Hospital from January 2021 to March 2023 were selected as the observation group, and 25 healthy individuals who underwent physical examination during the same period as the control group and 15 patients with chronic kidney disease as the chronic kidney disease group. In the observation group, there were 33 males and 27 females, aged (68.79±8.58) years. In the control group, there were 13 males and 12 females, aged (69.48±8.11) years. In the chronic kidney disease group, there were 9 males and 6 females, aged (70.12±8.09) years. Serum BNP and FGF-23 levels were detected and compared among the 3 groups by variance analysis, and the values of serum BNP and FGF-23 levels in predicting the severity of renocardiac syndrome were analyzed by receiver operating characteristic curve (ROC). Serum levels of BNP and FGF-23 were compared in patients with renocardiac syndrome with different cardiac function grading and renal function grading by variance analysis, and the correlations between serum BNP and FGF-23 levels and renal function grading and cardiac function grading were analyzed by Spearman rank correlation analysis. Results　Serum levels of BNP and FGF-23 [(456.48±64.48) mmol/L and (61.15±5.15) ng/L] in the observation group were higher than those in the chronic kidney disease group [(248.89±54.47) mmol/L and (47.48±4.78) ng/L] and the control group [(75.52±10.45) mmol/L and (30.44±4.49) ng/L], with statistically significant differences (F=448.625 and 346.409, both P<0.001). ROC analysis confirmed that serum levels of BNP and FGF-23 could predict the severity of renocardiac syndrome, with the areas under the curve of 0.690 and 0.941 (both P<0.05). Serum levels of BNP and FGF-23 [(346.48±34.14) mmol/L and (68.14±5.46) ng/L] in the patients with grade Ⅱ cardiac function were significantly lower than those in the patients with grade Ⅲ cardiac function [(651.15±86.15) mmol/L and (72.18±6.48) ng/L] and grade Ⅳ cardiac function [(819.15±94.58) mmol/L and (81.15±6.79) ng/L], with statistically significant differences (F=180.981 and 19.070, both P<0.001). Serum levels of BNP and FGF-23 [(348.48±32.45) mmol/L, (68.45±5.48) ng/L] in the patients with stage I renal function were significantly lower than those in the patients with stage II renal function [(456.18±45.15) mmol/L and (74.45±6.15) ng/L], stage III renal function [(784.15±56.15) mmol/L and (78.15±6.89) ng/L], and stage IV renal function [(826.45±64.15) mmol/L and (86.15±6.89) ng/L], with statistically significant differences (F=327.325 and 20.322, both P<0.001). Serum levels of BNP and FGF-23 were positively correlated with renal function grading and cardiac function grading (all P<0.05). Conclusions　Serum levels of BNP and FGF-23 are positively correlated with renal function grading and cardiac function grading in patients with renocardiac syndrome. Clinicians should closely monitor these indicators to predict the occurrence and progression of the disease.

Key words:

Renocardiac syndrome, Severity of the condition, Brain natriuretic peptide, Fibroblast growth factor 23